On July 24, Ningbo IPR Bureau said 4 Chinese pharmaceutical companies including Ningbo Tian Heng have successfully taken legal proceedings against a USA company. Patent Reexamination Committee of National IPR Department has announced that the patent applied by the USA Company is invalid in China. It symbolizes that Tian Heng can sell brand new anticancer medicine without patent’s obstruct. It is the first time that a Ningbo company to reverse the patent of a USA company.